The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Rathmell: We must put the individual at the center of our approach to ending cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Dear Colleagues,

When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.

This era is built on the foundations of decades of diligent work to deeply understand the various mechanisms that drive cancer. And it will evolve further as we arrive at even deeper understandings.

I am immensely grateful to the editorial staff for giving me this outlet, and I have been elevated by the avenue it presented to hear from more voices as guest editors. Our community is even richer and more connected than I ever realized. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
By Katie Goldberg
Clinical

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 
By Jacquelyn Cobb
Byline
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account